Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK.
Department of Urology, Faculty of Medicine, Menoufia University, Menoufia, Egypt.
BJU Int. 2022 Jan;129(1):72-79. doi: 10.1111/bju.15505. Epub 2021 Jul 5.
To report the health-related quality of life (HRQoL) after robot-assisted radical cystectomy and intracorporeal urinary diversion (iRARC), and to identify factors impacting on return to baseline.
Consecutive patients undergoing iRARC between January 2016 and December 2017 completed the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (EORTC-QLQ-C30) and EORTC-QLQ-Muscle-Invasive Bladder Cancer Module (EORTC-QLQ-BLM30) questionnaires before surgery and had a minimum of 12 months follow-up postoperatively.
A total of 76 patients met the inclusion criteria at 12 months. Neobladder (NB) cases (n = 24) were younger (57.0 vs 71.0 years, P < 0.001) and fitter than ileal conduit (IC) cases (n = 52), and had higher physical (100.0 vs 93.3, P = 0.039) and sexual functioning (66.7 vs 50.0, P = 0.013) scores at baseline. Longitudinal analysis of the EORTC-QLQ-C30 showed that physical (NB: 93.3 vs 100.0, P = 0.020; IC: 80.0 vs 93.3, P < 0.001) and role functioning scores (NB: 83.3 vs 100.0, P = 0.010; IC: 83.3 vs 100.0, P = 0.017) decreased and fatigue score (NB: 22.2 vs 11.1, P = 0.026; IC: 33.3 vs 22.2, P = 0.008) increased at 3 months in both diversion groups. Scores returned to baseline at 6 months except physical functioning score in IC patients that remained below baseline until 12 months (86.7 vs 93.3, P = 0.012). The global HRQoL score did not show significant change postoperatively in both groups. A major 90-day Clavien-Dindo complication was a significant predictor (odds ratio [OR] 0.11, 95% confidence interval [CI] 0.02-0.62; P = 0.012) of deteriorated global HRQoL score at 3 months, while occurrence of a late complication (OR 0.14, 95% CI 0.03-0.65; P = 0.013) was a predictor of deteriorated global HRQoL score at 12 months. Longitudinal analysis of the EORTC-QLQ-BLM30 showed that urinary problems (NB: 14.3 vs 38.3, P < 0.001; IC: 5.6 vs 19.1, P < 0.001) and future perspective (NB: 33.3 vs 44.4, P = 0.004; IC: 22.2 vs 44.4, P < 0.001) scores were better than baseline at 3 months. Sexual function deteriorated significantly at 3 months (NB: 8.3 vs 66.7, P < 0.001; IC: 4.2 vs 50.0, P < 0.001) and then showed improvement at 12 months but was still below baseline (NB: 33.3 vs 66.7, P = 0.001; IC: 25.0 vs 50.0, P < 0.001). Involvement in penile rehabilitation was shown to be a significant predictor (β 18.62, 95% CI 6.06-30.45; P = 0.005) of higher sexual function score at 12 months.
While most functional domains and symptoms scales recover to or exceed baseline within 6 months of iRARC, physical function remains below baseline in IC patients up to 12 months. Global HRQoL is preserved for both types of urinary diversion; however, postoperative complications seem to be the main driving factor for global HRQoL. Sexual function is adversely affected after iRARC suggesting that structured rehabilitation of sexual function should be an integral part of the RC pathway.
报告机器人辅助根治性膀胱切除术和体内尿流改道(iRARC)后的健康相关生活质量(HRQoL),并确定影响恢复基线的因素。
2016 年 1 月至 2017 年 12 月期间连续接受 iRARC 的患者在术前完成了欧洲癌症研究与治疗组织 30 项核心问卷(EORTC-QLQ-C30)和欧洲癌症研究与治疗组织肌肉浸润性膀胱癌模块(EORTC-QLQ-BLM30)问卷,并在术后至少 12 个月进行了随访。
12 个月时,共有 76 例患者符合纳入标准。与回肠导管(IC)组(n=52)相比,膀胱重建(NB)组(n=24)的患者年龄更小(57.0 岁 vs 71.0 岁,P<0.001)且体能更好,且在基线时具有更高的生理(100.0 分 vs 93.3 分,P=0.039)和性功能(66.7 分 vs 50.0 分,P=0.013)评分。EORTC-QLQ-C30 的纵向分析显示,生理(NB:93.3 分 vs 100.0 分,P=0.020;IC:80.0 分 vs 93.3 分,P<0.001)和角色功能评分(NB:83.3 分 vs 100.0 分,P=0.010;IC:83.3 分 vs 100.0 分,P=0.017)在 3 个月时下降,而疲劳评分(NB:22.2 分 vs 11.1 分,P=0.026;IC:33.3 分 vs 22.2 分,P=0.008)在这两个分流组中在 3 个月时增加。除了 IC 患者的生理功能评分在 12 个月时仍低于基线(86.7 分 vs 93.3 分,P=0.012)外,所有评分均在 6 个月时恢复至基线。两组患者术后的整体 HRQoL 评分均无显著变化。主要的 90 天 Clavien-Dindo 并发症是 3 个月时整体 HRQoL 评分恶化的显著预测因素(优势比[OR]0.11,95%置信区间[CI]0.02-0.62;P=0.012),而迟发性并发症(OR 0.14,95%CI 0.03-0.65;P=0.013)是 12 个月时整体 HRQoL 评分恶化的预测因素。EORTC-QLQ-BLM30 的纵向分析显示,3 个月时,尿问题(NB:14.3 分 vs 38.3 分,P<0.001;IC:5.6 分 vs 19.1 分,P<0.001)和未来展望(NB:33.3 分 vs 44.4 分,P=0.004;IC:22.2 分 vs 44.4 分,P<0.001)评分均优于基线。3 个月时,性功能显著恶化(NB:8.3 分 vs 66.7 分,P<0.001;IC:4.2 分 vs 50.0 分,P<0.001),然后在 12 个月时有所改善,但仍低于基线(NB:33.3 分 vs 66.7 分,P=0.001;IC:25.0 分 vs 50.0 分,P<0.001)。阴茎康复参与被证明是 12 个月时性功能评分更高的显著预测因素(β 18.62,95%CI 6.06-30.45;P=0.005)。
虽然 iRARC 后大多数功能域和症状量表在 6 个月内恢复到或超过基线,但在 12 个月时,IC 患者的生理功能仍低于基线。两种类型的尿流改道都能维持整体 HRQoL;然而,术后并发症似乎是整体 HRQoL 的主要驱动因素。iRARC 后性功能受到影响,表明应将性功能的结构化康复作为 RC 治疗路径的一个组成部分。